CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Brand Name||Tecentriq & Avastin|
|Generic Name||Atezolizumab & Bevacizumab|
|Strength||1200 mg/20 mL (60 mg/mL) vial & 100 mg/4 mL (25 mg/mL) and 400mg/16mL (25 mg/mL) vials|
|Indication||Non-Squamous Non-Small Cell Lung Cancer|
|Funding Request||For the treatment of metastatic EGFR and/or ALK positive non-squamous non-small cell lung cancer in patients who have progressed on treatment with targeted therapies. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should be continued until disease progression or unacceptable toxicity.|
|Pre Noc Submission||No|
|NOC Date||May 24, 2019|
|Manufacturer||Hoffmann-La Roche Limited|
|Sponsor||Hoffmann-La Roche Limited|
|Submission Date||November 18, 2019|
|Submission Deemed Complete||December 2, 2019|
|Stakeholder Input Deadline ‡||December 2, 2019|
|Check-point meeting||January 27, 2020|
|pERC Meeting||April 16, 2020|
|Initial Recommendation Issued||April 30, 2020|
|Feedback Deadline ‡||May 14, 2020|
|pERC Reconsideration Meeting||June 18, 2020|
|Final Recommendation Issued||July 3, 2020|
|Notification to Implement Issued||July 20, 2020|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.